bioMérieux マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Pierre Boulud

最高経営責任者

€2.5m

報酬総額

CEO給与比率	25.7%
CEO在任期間	1.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.3yrs
取締役会の平均在任期間	10yrs

経営陣の近況

Recent updates

CEO報酬分析

bioMérieux の収益と比較して、Pierre Boulud の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	€411m
Mar 31 2024	n/a	n/a	€384m
Dec 31 2023	€2m	€631k	€358m
Sep 30 2023	n/a	n/a	€372m
Jun 30 2023	n/a	n/a	€386m
Mar 31 2023	n/a	n/a	€419m
Dec 31 2022	€2m	€510k	€452m
Sep 30 2022	n/a	n/a	€502m
Jun 30 2022	n/a	n/a	€552m
Mar 31 2022	n/a	n/a	€577m
Dec 31 2021	€2m	€510k	€601m
Sep 30 2021	n/a	n/a	€555m
Jun 30 2021	n/a	n/a	€509m
Mar 31 2021	n/a	n/a	€457m
Dec 31 2020	€1m	€497k	€404m

報酬と市場: Pierreの総報酬 ($USD 2.59M ) は、 German市場 ($USD 4.86M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Pierreの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Pierre Boulud (53 yo)

1.3yrs

在職期間

€2,452,864

報酬

Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from July 01, 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operati...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Pierre Boulud	Chief Executive Officer	1.3yrs	€2.45m	データなし
Guillaume Bouhours	Executive VP of Purchasing and Information Systems & CFO	6.7yrs	データなし	データなし
Sylvain Morgeau	Investor Relations	no data	データなし	データなし
Audrey Dauvet	Executive Vice President of Legal	1.8yrs	データなし	データなし
Valerie Leylde	Executive Vice President of Human Resources	5.8yrs	データなし	データなし
Pierre Charbonnier	Executive Vice President of Global Quality	6.7yrs	データなし	データなし
Yasha Mitrotti	Executive Vice President of Industrial Applications	6.7yrs	データなし	データなし
Frederic Beseme	Head of CSR	4.8yrs	€21.99k	データなし
Jennifer Zinn	Executive Vice President of Clinical Operations	1.3yrs	データなし	データなし
Charles Cooper	Executive VP & Chief Medical Officer	less than a year	データなし	データなし
Celine Roger-Dalbert	Executive Vice President of Research & Development	less than a year	データなし	データなし
Franck Admant	Director of Investor Relations	no data	データなし	データなし

3.3yrs

平均在職期間

51.5yo

平均年齢

経験豊富な経営陣: EYWNの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Alain Merieux	Founding Chairman	7.3yrs	データなし	データなし
Jean-Luc Belingard	Non-Independent Director	18.2yrs	€52.00k	0.051% € 6.0m
Philippe Archinard	Non-Independent Director	14.4yrs	€61.00k	0.000030% € 3.5k
Alexandre Merieux	Chairman	20.6yrs	€1.92m	0.000050% € 5.8k
Harold Y. Boel	Independent Director	12.5yrs	€56.00k	0.00013% € 15.2k
Marie-Helene Habert-Dassault	Independent Director	12.5yrs	€44.00k	0.000050% € 5.8k
Fanny Letier	Independent Director	7.5yrs	€61.17k	0.000030% € 3.5k
Viviane Monges	Independent Director	less than a year	データなし	データなし
Marie-Paule Kieny	Independent Director	7.3yrs	€35.00k	0.00015% € 17.5k
Sylvain Orenga	Employee Representative Director	2.5yrs	€52.00k	データなし

10.0yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: EYWNの取締役会は経験豊富で経験豊富です ( 10年の平均在任期間)。

bioMérieux マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

bioMérieux S.A., Annual General Meeting, May 23, 2024

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A., Annual General Meeting, May 20, 2021

Recent updates

First half 2024 earnings released: EPS: €1.83 (vs €1.37 in 1H 2023)

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Upcoming dividend of €0.85 per share

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

New minor risk - Earnings quality

Dividend of €0.85 announced

Full year 2023 earnings released: EPS: €3.03 (vs €3.84 in FY 2022)

bioMérieux S.A., Annual General Meeting, May 23, 2024

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Upcoming dividend of €0.85 per share at 0.9% yield

Full year 2022 earnings released: EPS: €3.84 (vs €5.08 in FY 2021)

bioMérieux Introduces GENE-UP ENVIROPRO

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Upcoming dividend of €0.85 per share

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

First half 2021 earnings released: EPS €2.34 (vs €1.46 in 1H 2020)

Upcoming dividend of €0.62 per share

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Revenue misses expectations

New 90-day low: €110

bioMérieux S.A., Annual General Meeting, May 20, 2021

bioMérieux S.A. Announces the Expansion of the Ce Marking of Its Molecular Biology Argene® Sars-Cov-2 Diagnostic Test to Include Saliva Specimens

bioMérieux Launches Predictive Diagnostics, Pairing Microbiology Solutions with Data Science, Sequencing and Predictive Modeling

bioMérieux S.A. Issues No Annual Guidance for 2020

New 90-day high - €138

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34